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Use of p53-Silenced Endothelial Progenitor Cells to Treat Ischemia in
Diabetic Peripheral Vascular Disease
Nabanita Kundu, PhD; Cleyton C. Domingues, PhD; Cyril Chou, BS; Neeki Ahmadi, BS; Sara Houston, PhD; D. Joseph Jerry, PhD;
Sabyasachi Sen, MD
Background-—Peripheral vascular disease is a major diabetes mellitus-related complication. In this study, we noted that
expressions of proapoptotic p53 gene and its downstream cascade gene such as p21 are upregulated in hyperglycemia. Therefore,
we investigated whether p53- and p21-silenced endothelial progenitor cells (EPCs) were able to survive in hyperglycemic milieu,
and whether transplantation of either p53 knockout (KO) or p21KO or p53- and p21-silenced EPCs could improve collateral vessel
formation and blood flow in diabetic vaso-occlusive peripheral vascular disease mouse models.
Methods and Results-—We transplanted p53 and p21KO mouse EPCs (mEPCs) into streptozotocin–induced diabetic (type 1
diabetes mellitus model) C57BL/6J and db/db (B6.BKS(D)-Leprdb/J) (type 2 model) post–femoral artery occlusion. Similarly, Ad-
p53–silenced and Ad-p21–silenced human EPCs (CD34+) cells were transplanted into streptozotocin-induced diabetic NOD.CB17-
Prkdcscid/J mice. We measured blood flow at 3, 7, and 10 days and hindlimb muscles were obtained postsacrifice for mRNA
estimation and CD31 staining. Enhanced blood flow was noted with delivery of p53 and p21KO mEPCs in streptozotocin-induced
diabetic C57BL/6J mice. Similar results were obtained when human Ad-p53shEPCs(CD34+) and Ad-p21shEPCs(CD34+) were
transplanted into streptozotocin-induced nonobese diabetic severe combined immunodeficiency mice. Gene expression analysis of
p53 and p21KO EPCs transplanted hindlimb muscles showed increased expression of endothelial markers such as endothelial
nitric oxide synthase, vascular endothelial growth factor A, and platelet endothelial cell adhesion molecule 1. Similarly, quantitative
reverse transcriptase polymerase chain reaction of human Ad-p53shEPCs (CD34+)– and Ad-p21shEPCs (CD34+)–transplanted
hindlimb muscles also showed increased expression of endothelial markers such as vascular endothelial growth factor A, noted
primarily in the p53-silenced EPCs group. However, such beneficial effect was not noted in the db/db type 2 diabetic mouse
models.
Conclusions-—Transient silencing of p53 using adenoviral vector in EPCs may have a therapeutic role in diabetic peripheral
vascular disease. ( J Am Heart Assoc. 2017;6:e005146. DOI: 10.1161/JAHA.116.005146.)
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D iabetes mellitus affectsmore than 11% of US adults and isprojected to nearly double by 2025.1 The presence of
moderate hyperglycemia in addition to mild and moderate
obesity may confer significant cardiovascular risk.2 The Amer-
ican Diabetes Association has reported that coronary artery
disease and stroke are 3 times more common in prediabetic
compared with nondiabetic patients,3 and overt diabetes
mellitus increases this risk 5-fold. Many patients with predia-
betes are either overweight or obese. Both diabetes mellitus
and obesity are associated with cardiovascular complications
such as endothelial dysfunction, oxidative stress, endothelial
cell inflammation, and cardiovascular prothrombotic states.4
These complications are primary reasons of cardiovascular
disease. Cardiovascular disease includes cerebral, cardiac, and
peripheral vascular diseases (PVDs). In this study, our main
focuswill remain on PVD as a consequence of diabetesmellitus.
One of the major consequences of diabetes mellitus is
PVD. PVD is the inadequate perfusion of blood in the
peripheral arteries often triggered by atherosclerosis, one of
the major consequences of diabetes mellitus. Every day, 230
patients undergo diabetes mellitus-related amputation5 due to
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PVD. In these patients, PVD most often occurs secondarily to
total occlusion of major vessels in the limb such as the
femoral or tibial artery. Therefore, it is important to improve
blood flow and neovascularization to reduce amputation and
the use of cell therapy could be the possible solution in
diabetes mellitus-related PVD. Endothelial progenitor cells
(EPCs), precursor of mature endothelium, are good candidates
for cell therapy as they demonstrate regenerative properties.
Therefore, use of EPCs is promising for the treatment of
ischemia-related complications in the diabetic population.
EPCs are stem/progenitor cell precursors from the
hematopoietic stem cell lineage6 and are often referred to
as circulating progenitor cells. Given the appropriate environ-
mental conditions, EPCs can perform beneficial angiogenic
and vascular repair functions, including incorporation into the
endothelium and release of growth factors and cytokines that
promote repair.7,8 Cell sorting for CD34+ identifies stem-like
cells with endothelial/hematopoietic lineage markings.9,10
Controversy regarding the precise definitions of endothelial
progenitor and other angiogenic cells has slowed progress in
the field.9 It is generally agreed upon that EPCs (CD34+)
contribute to the maintenance of vascular endothelial integrity
through actions of particular endothelial lineage–directed
subsets or by acting as a pool of generic progenitors.10 In
addition, EPCs (CD34+) have recently received a great deal of
attention in the literature for their cell therapy applications.11
However, EPCs (CD34+) are susceptible to adverse in vivo
environments. Cardiometabolic disease and diabetes mellitus
reduces the mobilization and circulating number of EPCs
(CD34+).12 Recently, EPCs (CD34+) and colony count were
reported to be lower in prediabetes mellitus patients.13 In
addition, EPCs (CD34+) isolated from diabetic patients were also
unable to incorporate into damaged vessels andpromote repair.14
Current studies have shown that the degree of collateral
vessel formation is important for salvaging an ischemic
leg,15,16 and having EPCs (CD34+) at or near the site of
vascular occlusion has yielded a positive outcome in not only
animal models8,17,18 but also human subjects in a setting of
intractable angina.19,20 However, for the EPCs (CD34+) to be
effective posttransplantation, the progenitor cells need to
survive in proapoptotic, hyperglycemic conditions.
In this study, we investigated whether EPCs (CD34+) can
survive in hyperglycemia (20 mmol/L glucose) with genetic
modification, and whether such modified EPCs (CD34+) can
contribute effectively to revascularization in diabetic PVD.
Methods
In Vitro Cell Culture
Mouse EPCs (mEPCs) were obtained as described in our
protocol previously.18 Briefly, mouse peripheral blood
mononuclear cells were isolated from circulating whole blood
(collected from 3 mice in each category) by the Ficoll
separation method. These cells were then cultured in EGM-2
media (Lonza Inc, Basel, Switzerland) for 5 to 7 days and
trypsinized to collect and transplant to mice.
Human umbilical vein endothelial cells (HUVECs) were
obtained from Lonza and were cultured in growth factor–
supplemented EGM-2 media in a humidified 37°C incubator
containing 5% CO2 using procedures previously described.
21
Media was changed every 2 to 3 days. HUVECs were exposed
to normal (5.5 mmol/L) and high glucose (20 mmol/L) for
28 days. Cells were collected for gene expression and
mitochondrial respiration analysis at days 7, 14, and 28.
Human peripheral blood mononuclear cells were also
isolated from circulating whole blood by the Ficoll separation
method. Human EPCs (CD34+) were then magnetically sorted
using CD34 microBeads (human) antibody (Miltenyi Biotec,
Bergisch Glagbach, Germany) and cultured in StemSpan SFEM
II media (STEMCELL Technologies, Vancouver, Canada) for
2 days. Cells were then exposed to normal (5.5 mmol/L) and
high glucose (20 mmol/L) for 48 hours in EGM-2 media
before they were harvested for gene expression analysis. We
followed institutional review board and Institutional Animal
Care and Use Committee guidelines for this study and it was
approved by appropriate institutional committees.
RNA Extraction, cDNA Synthesis, and Gene
Expression in Human Umbilical Vein Endothelial
Cells and Endothelial Progenitor Cells
Quantitative reverse transcriptase polymerase chain reaction
was used for gene expression analysis. Total mRNA from both
HUVECs and EPCs were isolated by RNeasy Mini Kit (Qiagen,
Hilden, Germany). The T100 Thermal Cycler (Bio-Rad, Her-
cules, CA) was used to convert mRNA to cDNA by using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). The CFX96 Real-Time qPCR
System (Bio-Rad) was used to analyze the genes of interest by
using TaqMan Universal Master Mix II (Applied Biosystems,
Foster City, CA). Individual gene expression was normalized to
housekeeping genes 18S or GAPDH.
Oxygen Consumption Rate Analysis
Oxygen consumption rate (OCR) of HUVECs exposed to
normal (5.5 mmol/L) and high (20 mmol/L) glucose was
analyzed using Extracellular Flux Analyzers XFp (Seahorse
Bioscience). Thirty-thousand HUVECs per well were seeded in
V7-PS mini-plates and cultured in a humidified 37°C incubator
containing 5% CO2 for 24 hours. After washing with assay
medium (nonbuffered XF Base Medium Minimum DMEM
[Seahorse Bioscience] pH 7.4, containing 5.5 mmol/L
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glucose, 1 mmol/L pyruvate, and 2 mmol/L glutamine) cells
were kept in a CO2-free incubator at 37°C for 45 minutes
before assay. During the mitochondrial stress test, 3 injec-
tions were performed: oligomycin (1.1 lmol/L), carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (2.08 lmol/L),
and rotenone and antimycin (0.5 lmol/L). Basal respiration
was subsequently measured.
Ex-Vivo Lentiviral Gene Transduction
Replication-deficient lentiviral construct was used to silence
mouse p53 genes in mEPCs. The replication-deficient lentiviral
constructs containing green fluorescent protein that were used
in this study have been previously developed and tested by
Ventura et al.22 The plasmids used for the lentivirus construct
were obtained from Dr Joseph Jerry’s laboratory at Pioneer
Valley Life Sciences Institute, Springfield, MA. The virus was
packaged and propagated using standard NIH/3T3 fibroblasts
and human embryonic kidney 293 cell lines. The vector titer
used was 50 multiplicity of infection. Control for the Lenti-GFP-
p53sh that is Lenti-GFP-Null constructs were obtained from
Cell Biolabs Inc (San Diego, CA; catalog number LTV-400).
Ex Vivo Adenoviral Gene Transduction
Ad-human-P53 (TP53)-shRNA (Vector Biolabs, Malvern, PA)
was used to silence p53 and AdU6-Human-CDKNIA-shRNA
(Vector Biolabs) was used to silence p21. Adenovirus was
propagated and titered using human embryonic kidney 293
cells (Lonza). After isolation of EPCs (CD34+) from peripheral
blood mononuclear cells, cells were cultured in StemSpan
SFEM II media for 5 days. Cells were subsequently transduced
by virus at 100 multiplicity of infection and kept in culture for
another 4 to 5 days before transplantation in mouse.
Propidium Iodide, Annexin V Staining, and
Fluorescence-Activated Cell Sorting Analysis
Human EPCs (CD34+) following hyperglycemia (20 mmol/L
glucose) exposure were stained with propidium iodide
(Miltenyi Biotec, 130-093-233) and annexin V (Miltenyi Biotec,
130-097-928) along with suggested isotype control using
Miltenyi Biotec standard protocols. Both human EPCs
(CD34+) and HUVECs were stained with propidium iodide.
The cells were analyzed poststaining using BD FACSCalibur
(BD Biosciences) cell analyzer.
Animals Used
Adult male (aged 4–6 weeks), wild-type (WT) mice (C57/BL6),
p21 knockout (KO) B6.129S6(Cg)-Cdkn1atm1Led/J), p53KO
(B6.129S2-Trp53tm1Tyj/J), db/db (B6.BKS(D)-Leprdb/J),
nonobese diabetic severe combined immunodeficiency (NOD-
SCID) mice (NOD.CB17-Prkdcscid/J) were purchased from
Jackson Laboratory. A normal diet (Harlan Teklab, Global 19%
Protein Extruded Rodent Diet, catalog # 2019S) was provided
throughout experimentation, and 12-hour artificial light-dark
cycle was maintained while the room temperature was kept at
21°C. For C57/BL6 and NOD.CB17-Prkdcscid/J as a PVD
model, we used n=3 mice per group.
p53 global KO animals on C57Bl6 and Balb/c background
were obtained from Dr Jerry’s laboratory. The mice obtained
from Dr Jerry’s laboratory that were p53 silenced (either on
C57Bl6 or BalB/c background) were genotyped for confirma-
tion by tail-snip genotyping. Only homozygous animals were
used to obtain p53KO EPCs. Institutional guidelines were
followed for all animal procedures (Baystate Medical Center,
Pioneer Valley Life Sciences Institute, Springfield, MA, and
The George Washington University, Washington, DC).
Streptozotocin-Induced Hyperglycemia
Type 1 diabetesmellitus was induced inWT andNOD-SCIDmice
by intraperitoneal injection of streptozotocin (STZ). Tail vein
blood glucose level was tested (by contour next blood glucose
meter) at day 0 after 6 hours of fasting before STZ injection.
Doses of STZ 40 mg/kg bodyweight were administered for 3 to
5 consecutive days. By 1 to 2 weeks post-STZ injection, mouse
tail vein blood glucose was checked to verify hyperglycemia
(>250 mg/dL). Before surgery and transplanting EPCs, mice
blood glucose was rechecked to confirm hyperglycemia.
Animal Surgery and Postoperative Care
Mice were anesthetized by isoflurane (according to guidelines
previously described18) before operation. The right hind leg
was shaved and cleaned, followed by cleaning with 70%
ethanol solution and exposure of the femoral artery. The
femoral artery was ligated proximally and distally using
absorbable sutures. The artery was cut in between the
ligatures and the ends of the arteries were cauterized.
Approximately 39105 EPCs were injected around the ligature
site for each genotype. For control animals, saline was
injected instead of cells. The skin was closed and sutured
back using nonabsorbable sutures in an interrupted pattern.
Mice were carefully monitored postoperation for 3 days, and
Buprenex analgesic at a dose of 0.1 mg/kg body weight was
injected twice a day to relieve postoperative pain. Saline was
also administered (subcutaneous) to maintain hydration.
Laser Doppler Imaging
Laser Doppler perfusion imaging was used to assay limb
vasculature perfusion. Mice were anesthetized as described
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above (see Method: Animal Surgery and Postoperative Care)
before imaging. Mice were placed on a ventral surface and
exposed against black background, followed by shaving of
both hindlimbs. Vascular perfusions in both right and left
hindlimbs were measured and analyzed using a Moor LDI
Laser Doppler Imager (version 5.3). Images were acquired at
days 3, 7, and 10 postocclusion of femoral artery for most
experiments. The blood perfusion value obtained from the
analyzed image of the right hindlimb (surgery/ischemic) was
normalized to value of left (no surgery/nonischemic) hindlimb
to calculate the ratio of blood perfusion for each mouse.
RNA Extraction, cDNA Synthesis, and Gene
Expression of Hindlimb
Mouse hindlimb quadriceps (right and left) were flash frozen in
liquid nitrogen after harvesting at day 28 postsurgery and
kept at 80°C. Frozen tissue was then homogenized and total
RNA was isolated using an RNeasy Lipid Tissue Mini Kit
(Qiagen). For cDNA conversion and quantitative reverse
transcriptase polymerase chain reaction, we followed the
same methodology as previously discussed (see Method: RNA
Extraction, cDNA Synthesis, and Gene Expression in HUVECs
and EPCs).
Immunohistochemistry
Immunohistochemistry was performed to quantify platelet
endothelial cell adhesion molecule 1 (PECAM-1; CD31)
expression in right and left hindlimb muscles. CD31 antibody
was diluted at a 1:100 ratio (Abcam) and horseradish
peroxidase–conjugated anti-Rat ImmPress (RTU) was used
as a secondary antibody followed by 3,30-diaminobenzidin
staining.
Statistical Analysis
Results were analyzed using multiple paired t test where
*P<0.05, **P<0.01, and ***P<0.005 were considered signif-
icant. The Bonferroni-Dunn method was used to correct
multiple comparisons. Every statistical analysis was per-
formed based on at least two biological or biochemical
repetitions.
Results
In this study, one of our primary goals was to assess the
effect of hyperglycemia on EPCs. One of the approaches was
to measure apoptosis. To test the degree of apoptosis, human
EPCs (CD34+) were exposed to normal glucose and high
glucose concentrations (5.5 and 20 mmol/L, respectively) for
48 hours, followed by fluorescence-activated cell sorting
analysis. Human EPCs (CD34+) were also stained with
annexin V, a marker for early stages of apoptosis, and
propidium iodide, a marker for late or advanced stages of
apoptosis. For both staining methods, the results showed
features of apoptosis of EPCs (CD34+) upon hyperglycemic
exposure conditions (Figure 1A through 1C). However, mature
endothelial cells such as commercially obtained HUVECs did
not exhibit any apoptotic effect, even after 10 days of
hyperglycemic exposure (Figure 1D).
Another approach was targeted gene expression analysis
to examine the effect of high glucose on EPCs. For this
purpose, quantitative reverse transcriptase polymerase chain
reaction of EPCs (CD34+) was performed with a primary focus
on apoptosis cascade and inflammation pathways. We
observed that p53 gene was upregulated significantly when
cells were exposed to high glucose. Moreover, p21 genes as
well as certain vascular marker genes such as vascular
endothelial growth factor receptor 2 (kinase insert domain
receptor) and PECAM-1 were also upregulated (Figure 2A). On
the other hand, when HUVECs were exposed to hyper-
glycemic conditions, the upregulation of those genes (p53,
p21, kinase insert domain receptor, PECAM-1, and interleukin
6) was more evident at day 28 in comparison to days 7 and 14
(Figure 2B).
Interestingly, mitochondrial function experiments using
HUVECs demonstrated that OCR between cells exposed to
normal and high glucose conditions becomes very distinct at
day 28 when the OCR dropped significantly for high glucose–
exposed cells compared with cells cultured in normal glucose
(Figure 3).
Based on our results of fluorescence-activated cell sorter
and gene expression studies (Figures 1 through 3), we
noted that human EPCs (CD34+) are susceptible to
hyperglycemic (20 mmol/L) injury (Figure 1A through 1C)
at an earlier time point, compared with HUVEC. Therefore,
for better survival of EPCs, in hyperglycemic milieu, we
decided to silence p53 and p21 genes and verify whether
KO or silencing of p53 and p21 (individually) would protect
mEPCs and human EPCs (CD34+) from hyperglycemia-
mediated apoptosis.
p53KO mEPCs were identified microscopically as mature
and robust (Figure 4A and 4B) and were able to differentiate
further into mature endothelium-like cells (cobblestone
appearance) following 28 days of culture at normoglycemic
conditions (5.5 mmol/L glucose) (Figure 4C). The improved
survival of mouse p53KO EPCs were noted in mice with both
C57Bl6 and BalbC background; however, only data with
C57Bl6 mEPC are shown. The mouse p53KO EPCs progressed
onto capillary-like structures, indicating an endothelial cell–
like property (Figure 4D). Lentivirus-transduced p53sh-mEPCs
also showed improved survival compared with null-transduced
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cells in hyperglycemic conditions, with cell survival differ-
ences more prominent as the number of days in culture
increased from days 1 to 7 (Figure 5A).
As the next step, we silenced p53 and p21 for a shorter
period (transient silencing) using a DNA virus, such as
adenovirus, rather than a long-term silencer–like lentivirus,
so that the long-term silencing effects of p53 and p21 could be
avoided. In fact, adenoviral p53 silencing allowed reduction of
both p53 and p21 mRNA expression, while expression of key
endothelial function genes such as endothelial nitric oxide
synthase, von Willebrand factor, and PECAM-1 were main-
tained even at 28 days of culture (Figure 5B). Moreover,
Ad-p53sh transduction prevented hyperglycemia-mediated
p53 and p21mRNA overexpression. Similarly, Ad-p21 silencing
prevented p21 mRNA overexpression in hyperglycemia, and
even reduced upstream p53 expression to a certain extent
(Figure 5C).
To verify the beneficial effects of p53 and p21 silencing
in vivo, STZ-induced type 1 diabetic mice were subjected to a
femoral artery occlusion (PVD model) and p53 and p21KO
mEPCs (obtained from peripheral blood of global p53 and
p21KO mice) were transplanted intramuscularly post–femoral
artery occlusion. Laser Doppler imaging between days 3 and
10 showed improved vascular flow, most significantly in the
p53KO mEPCs group (n=3) (Figure 6A and Figure S1). Post
sacrifice, (four weeks following transplantation of EPCs), we
observed upregulation of vascular marker genes such as
vascular endothelial growth factor A, PECAM-1, endothelial
nitric oxide synthase, and kinase insert domain receptor by
gene expression analysis of quadriceps muscles compared
with saline and WT mEPCs transplanted mice (Figure 6B).
However, CD31 staining did not show a significant difference,
although a distinct trend of increased capillary density in
hindlimb muscles were noted in mice that received p53-
silenced EPCs (Figure 6C). p21KO mEPCs were less effica-
cious than p53KO mEPCs.
Evaluation of the efficacy of p53-silenced mEPCs using a
lentiviral vector in STZ mice showed similar findings as
described for p53KO mEPCs. p53-silenced mEPCs trans-
planted in STZ-induced diabetic mice clearly improved
Figure 1. Fluorescence activated cell sorter (FACS) analysis of EPCs (CD34+) and HUVECs exposed to
normal glucose (NG) and high glucose (HG): Human EPCs (CD34+) were exposed to NG (5.5 mmol/L) and
HG (20 mmol/L) for 48 hours followed by FACS Analysis. A, Annexin V stained cells and B, Propidium
iodide stained EPCs (CD34+) demonstrated significant degree of apoptosis takes place within 48 hours of
high glucose exposure. To compare effect of NG and HG on endothelial progenitor and mature endothelial
cells, C, human EPCs (CD34+) and D, HUVECs were exposed to NG and HG for 48 hours and 10 days,
respectively, and cells were stained with propidium iodide. EPCs (CD34+) showed increased apoptosis by
48 hours of high glucose exposure. However, HUVECs did not show any apoptotic change even after
10 days of HG exposure compared to NG exposed cells. These data demonstrate that EPCs are more
susceptible to HG mediated injury compared to mature endothelial cells (HUVECs).
DOI: 10.1161/JAHA.116.005146 Journal of the American Heart Association 5






















vascular flow compared with both lenti-null–transduced EPCs
(1 million mEPCs) and the saline group (n=3) (Figure S2).
Next, we used ex vivo p53- and p21-silenced (adenovirus
mediated) human CD34+ cells for transplantation in STZ-
induced diabetic NOD-SCID mice. The results for adenovirus-
transduced p53-silenced peripheral blood–derived human
EPCs (CD34+) transplantation to NOD-SCID mice showed that
secondary to p53 silencing, blood flow increased when p53-
silenced EPCs (CD34+) were transplanted into NOD-SCID mice
(Figure 7A and Figure S3), whereas p21-silenced CD34+ cell
transplantation did not show improved efficacy over adenovirus
null EPCs (n=3). Vascular markers such as vascular endothelial
growth factor A was upregulated significantly in the p53-
silenced group, more so than the p21-silenced group
(Figure 7B), in the quadriceps muscles compared with saline.
Collectively, these results prove that p53-silenced mEPCs or
Figure 2. Gene expression analysis of EPCs (CD34+) and HUVECs exposed to high glucose (HG) and
normal glucose (NG). Human EPCs (CD34+) were exposed to NG (5.5 mmol/L) and HG (20 mmol/L) for
48 hours. A, Upregulation of apoptotic genes (both p53 and p21) was observed due to HG exposure. B,
HUVECs showed upregulation of apoptotic (p53 and p21), platelet endothelial cell adhesion molecule 1
(PECAM-1) and inflammatory (IL6) genes after 28 days of HG exposure compared with 7 and 14 days,
indicating that HG effects are not fully apparent in HUVECs until 28 days. *P<0.05.
Figure 3. Oxygen consumption rate of HUVECs exposed to normal glucose (NG) and high glucose (HG). HUVECs were exposed to NG
(5.5 mmol/L) and HG (20 mmol/L) for 7, 14, and 28 days followed by oxygen consumption rate measurement during a mitochondrial stress
test. A and B, No significant change in between NG and HG exposed cells was observed at day 7 and 14. C, Lower respiration rate of HUVECs
was noted only after 28 days of high glucose exposure. Additives injected are indicated with arrows: a. Oligomycin-1.1 lmol/L, b. FCCP-
2.08 lmol/L and c. Rot/AA-0.5 lmol/L. These data demonstrate reduced oxygen consumption rate of mature endothelial cells (HUVECs)
exposed to hyperglycemic environment for a prolonged time (28 days). These results are representative of 3 independent experiments.
*P<0.05.
DOI: 10.1161/JAHA.116.005146 Journal of the American Heart Association 6






















human EPCs (CD34+) are more efficacious for vascular
regeneration compared with p21-silenced cells. Interestingly,
reverse transcriptase polymerase chain reaction of the quadri-
ceps from this group for interleukin 6, a prominent inflammatory
molecule, showed reduced expression in the animals that
received p53-silenced CD34+ cells compared with null-
transduced cells or saline, implying a reduction of inflammation
post–p53-silenced cell therapy in PVD (Figure S4).
However, in a type 2 diabetic obese mouse model (db/db),
neither p53KO mEPCs nor p21KO mEPCs showed any advan-
tage over WT mEPC delivery (Figure 8A through 8C) (n=2).
Discussion
The hyperglycemic condition in diabetic patients is a major
cause of endothelial dysfunction and cardiovascular
disease.23 Previous studies have shown that EPC-based cell
therapy is useful for repairing cardiovascular injury.8,17–20 In
our study, we reported increased cellular apoptosis in EPCs
within 48 hours in response to hyperglycemia, whereas in
HUVECs this effect was observed almost 4 weeks after cells
were exposed to hyperglycemic condition. This outcome was
confirmed by both gene expression (quantitative reverse
transcriptase polymerase chain reaction) and OCR measure-
ments. Collectively, these results indicate that EPCs (CD34+)
are more susceptible to hyperglycemia compared with
mature endothelial cells. Therefore, we can infer, diabetes
mellitus and associated hyperglycemia is a proapoptotic
condition that primarily affects EPCs more quickly (within
48 hours of hyperglycemia) than the mature endothelial
cells, such as HUVECs. It takes 28 days to show a similar
effect in HUVECs.
A B C D
Figure 4. Comparison of survival between mouse peripheral blood-derived wild type EPCs and p53KO EPCs. A, Rodent (wild type C57Bl/6
mice) peripheral blood-derived EPCs exposed to normoglycemia showed poorly cell surviving in culture media at day 14. B, p53KO mice derived
EPCs looked more mature and robust at day 14 of culture. C, At day 28, cells (shown at B) presented classical appearance of cobble stone
endothelial cells. D, Cells shown in (C) have formed capillary-like structures in matrigel, as a result of endothelial cell properties.
Figure 5. Effect of p53 and p21 silencing in EPCs. A, Silencing of p53 gene in mouse EPCs (mEPCs) by lentivirus as a vector demonstrates
improved survival in hyperglycemic condition compared to null lenti (non-silenced) transduced cells. Numbers of viable mEPCs are shown at
days 1, 3, and 7 postexposures to high glucose (20 mmol/L). B, Gene expression analysis showed, p53 silencing in mouse EPCs by adenovirus
down regulated p53 and p21 gene. Although, p53 silencing did not impair mRNA expression levels of critical endothelial marker gene such as
endothelial nitric oxide synthase (eNOS), von Willebrand factor (vWF), and platelet endothelial cell adhesion molecule 1 (PECAM1). C, Human
EPCs (CD34+) were transduced to silence p53 and p21 genes using adenovirus constructs and then exposed to high glucose for 48 hours.
Silencing of both p53 and p21 in hEPCs were confirmed by the reduced gene expression in comparison to Ad-null transduced cells, exposed to
hyperglycemia. *P<0.05.
DOI: 10.1161/JAHA.116.005146 Journal of the American Heart Association 7






















Additionally, our results suggest that by the time hyper-
glycemia affects endothelium such as HUVECs, endothelial
progenitors have already undergone apoptosis and are
possibly already depleted. Thus, it can be predicted that
endothelial damage and vascular complications of
hyperglycemia take time to develop, but, once the damage
has occurred, the chances of vascular regeneration are poor
as the progenitor pool is already depleted. This observation is
similar among epidemiological studies, where vascular com-
plications or endothelial dysfunction takes about 5 to 7 years
Figure 6. Enhanced vascularization in hind limb of Type 1 diabetes mellitus mouse model, posttransplantation of p53KO and p21KO
EPCs. Type 1 diabetes mellitus was induced in C57BL/6J mice by STZ. p53KO and p21KO mouse EPCs were transplanted to mouse
right hind limb quadriceps muscle, postocclusion of femoral artery. A, Blood flow was measured by Laser Doppler Perfusion Imager
(LDPI) system after surgery (3, 7, 10 days). Increased blood flow was noted with delivery of p53KO (green line) and p21KO (purple line)
EPCs, compared to WT (wild type; red line) and saline (blue line). B, Gene expression analysis was performed in quadriceps after mice
were sacrificed at day 28. Upregulation of mature endothelial markers such as vascular endothelial growth factor A (VEGF-A), platelet
endothelial cell adhesion molecule 1 (PECAM1), endothelial nitric oxide synthase (eNOS), and kinase insert domain receptor (KDR)
were observed in quadriceps from mice that received p53KO EPCs (statistical analysis was performed by using saline and WT EPC
receiving muscle as control). C, Quadriceps were stained with CD31 antibody and an increased number of capillaries were observed in
p53KO observed in quadriceps from mice that received p53KO EPCs. *P<0.05, **P<0.01 and ***P<0.005.
Figure 7. Enhanced vascularization in hind limb of diabetic mouse model posttransplantation of p53 and p21 silenced
human EPCs. Type 1 diabetes mellitus was induced in NOD.CB17-Prkdcscid/J mouse (NOD-SCID) by STZ. Simultaneously,
human EPCs were transduced with Adenovirus constructs to silence p53 and p21. Then, p53sh and p21sh human EPCs
were transplanted to mouse right hind limb muscle postocclusion of femoral artery. A, Blood flow was measured by Laser
Doppler Perfusion Imager (LDPI) system after surgery (3, 7, 10 days). Increased blood flow was noted with delivery of both
p53 silenced EPCs (green line) and p21 silenced EPCs (purple line) compared to Adenovirus null transduced EPC (red line)
delivery and saline (blue line). B, Gene expression analysis was performed in quadriceps after mice were sacrificed at day 28
postsurgery. Significant upregulation of mature endothelial marker such as vascular endothelial growth factor A (VEGF-A)
was observed in muscles that received p53sh (p53 silenced) observed in quadriceps from mice that received p53sh EPCs
(statistical analysis was performed by using saline and wild type EPC as control). However, no difference was observed in
muscles that received p21sh EPCs. C, No significant difference was noted in capillaries numbers when quadriceps were
stained with CD31 antibody. *P<0.05.
DOI: 10.1161/JAHA.116.005146 Journal of the American Heart Association 8






















to manifest, but, once the vascular complications are noted,
the repair or vascular regeneration is difficult as the
progenitor cell pool is depleted and the vascular complica-
tions are progressive from there on.1,3,14 This highlights the
fact that interventions to treat endothelial dysfunction needs
to precede EPC damage and needs to start early.
Interestingly, when we tried to culture mouse peripheral
blood–derived EPCs in normoglycemic EBM-2 media, we noted
significant and progressive cell death. However, when p53KO
mEPCs were cultured, we noted that the mouse endothelial
cells appeared to retain all properties of mature endothelium,
including tube formation in Matrigel. This finding indicates that
suitable culture media for mEPCs have not yet been formu-
lated, but protection from apoptosis does help cells grow to
maturity within 28 days. Simultaneously, it also indicates that
knocking down or suppression of p53 could be beneficial for
cell survival in a proapoptotic condition. We decided to use this
phenomenon to address diabetes mellitus-associated PVD. We
used an STZ-induced diabetic PVD mouse model and db/db
mice models to examine the effect of p53 and p21 suppres-
sion. We decided to test p21 silencing along with p53 silencing
as we had hoped that silencing a downstream protein from
p53 would reduce the off-target effects of p53 silencing.
To evaluate the effect of transplanted p53KO and p21KO
(downstream to p53 in apoptotic cascade) mEPCs in STZ-
induced diabetic mice, we used 3 outcome measures: blood
flow, mRNA gene expression of the right hind muscle at the
site of occlusion (that received EPC or saline deliver)
compared with the untouched left leg, and CD31 capillary
density measurement of the right leg compared with the right.
We observed that p53KO rather than p21KO had more
consistent improved results compared with WT cell therapy
showing improved blood flow and vascularization. However,
we were unable to observe statistically significant change in
capillary density measurement, although our experiments
showed improved trend with p53-silenced cell therapy.
Taking all of our outcome measures in an STZ mouse
model using genetically modified mEPCs, our results indicate
that p53KO and p21KO EPC transplantation showed better
viability than WT EPCs and proved beneficial to promote
increased blood flow to ischemic hindlimb, although p53KO
showed superiority over p21KO.
Since knocking down of apoptotic genes such as p53 and
p21 long term is not a realistic clinical approach as a cell
therapy, we investigated whether silencing of p53 would
indicate the same outcome as knocking down. We noted that
lentivirus-mediated p53 silencing in mEPC did improve cell
survival in high glucose, where cell depletion was rapid
otherwise, over 7 days. Similarly, mEPCs with lentivirus-
mediated p53 silencing showed improved blood flow by laser
Doppler (Figure S2). In order to obtain a translational benefit,
we speculated that one can use similarly modified human
cells for therapy in diabetic PVD. However, we decided not to
use a lentiviral construct, as application of a mutagenic
lentivirus in humans and suppressing p53 for long periods
may not be safe in spite of efficacy.
To solve this problem, we used short-term silencing of p53
where the viral construct would not be viable beyond 28 days.
Effects of adenoviral silencing usually persist 28 days.24,25
This time span is perfect because the time required by EPCs
to transform to a mature endothelium is also 28 days.
Simultaneously, we did not want to use a turn-on, turn-off
gene promoter, with another DNA virus like adeno-associated
virus,18,21 as the effect of silencing could be considered as
Figure 8. Enhanced vascularization in hind limb of obese diabetic Leptin resistant (db/db) mouse model posttransplantation
of p53KO and p21KO mouse EPCs. p53KO and p21KO mouse EPCs were transplanted to mouse (B6.BKS(D)-Leprdb/J) right hind
limb muscle postocclusion of femoral artery. A, Blood flow was measured by Laser Doppler Perfusion Imager (LDPI) system after
surgery (3, 7, 10 days). No statistical difference was noted with delivery of p53KO (purple line) and p21KO (green line) EPCs,
compared to WT (wild type; red line) and saline (blue line). B, Similarly, gene expression analysis data unable to show any
improvement due to gene silencing. C, No statistical difference in the number of capillaries were observed when quadriceps was
stained with CD31 antibody between operated and non-operated side.
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“leaky.”24,26 Thus, the use of an adenovirus as a gene
modification vector was the best selection, with a transduc-
tion efficacy profile better than liposomes.24,25
Adenovirus, unlike lentivirus, is a DNA virus and does not
integrate with the host genome.24,25,27 It can also provide
gene expression or a silencing effect for up to 4 weeks,24,27
which should be enough for EPCs transition to mature
endothelium. In our experience, efficacy with adenovirus is
about 30% to 40% compared with lentivirus, where the
efficacy is about 70% to 80%. For the purposes of this study,
adenovirus was chosen as the ideal vector for transient
silencing of p53 and p21. Using adenoviral constructs, we
were able to protect EPCs in hyperglycemia. Transplanting
p53- and p21-silenced human EPCs (CD34+) by adenoviral
vector improved blood flow, gene expression, and capillary
formation (Figure 7A and 7B) similar to our results using
genetically modified mEPCS (Figure 6A and 6B). However,
p53sh human CD34+ cells showed superiority over p21sh
human CD34+ cells.
When we used p53KO and p21KO mEPCs to treat vaso-
occlusive disease in a db/db mouse model (type 2 diabetes
mellitus mouse model), we did not note improvement in blood
flow by laser Doppler or in capillary density estimation,
indicating that p53 or p21 silencing may not be enough to
protect mEPCs in a type 2 rather than type 1 diabetes mellitus
mouse model. Type 2 diabetes mellitus has added adipocyte
inflammation along with hyperglycemia as a proapoptotic
agent. This could also mean that a higher number of modified
cells for therapy may be required to obtain a discernable
improvement compared with a type 1 model.
Our data also suggest that p53 silencing is not only
superior to unmodified EPCs but also has better outcome
efficacy than p21 silencing, particularly in a type 1 model.
Moreover, p53 silencing offers protection predominantly in a
type 1 diabetes mellitus environment where hyperglycemia is
the primary apoptotic agent.
We expected that p21 silencing would afford protection
and vascular regeneration effectiveness similar to p53
silencing so that off-target effects of p53 silencing would be
minimized. Although p21-silenced EPCs did not work as
expected, p53 silencing showed positive results and can
emerge as a promising therapeutic intervention for ischemic
type 1 diabetic complication. p53 silencing provided protec-
tion and improved survival of EPCs, which subsequently
improved vascular regeneration postocclusion, which could be
secondary to its paracrine properties.
Conclusions
Our data indicate that using genetically modified EPCs
(CD34+) transplantation can usher in new hope for reducing
vascular damage in type 1 diabetic patients where
microvascular disease such as retinopathy, nephropathy,
and neuropathy are more common.
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Supplemental figure 1: Images of enhanced vascularization in hind 
limb of STZ induced type I diabetic mouse model (C57BL/6J), post-
transplantation of p53KO and p21KO EPCs. Serial laser Doppler 
images showing improved circulation at day 10 in the right leg, 
particularly in the group that received p53 KO EPCs. 







Figure 2: Images of enhanced vascularization in hind limb of STZ induced diabetic 
mouse model, following transplantation of p53silenced (by Lentivirus) mouse EPCs. 
Serial laser Doppler images showing improved circulation at day 11 in right leg particularly 
in the group that received p53 silenced EPCs. Lentivirus was used to silence mouse p53 
and the results were compared to mouse that received Lenti-Null transduced EPCs or 
saline. 







Supplemental figure 3: Enhanced vascularization in hind limb of STZ induced 
diabetic mouse model (NOD-SCID Type 1 Diabetes mice), post-transplantation of 
p53sh and p21sh human EPCs (silenced by adenoviral construct): Serial laser 
Doppler images showing improved circulation at day 10 in right leg, particularly in the 
group that received p53sh EPCs. 








Supplemental figure 4: Reduced inflammation in hind limb of STZ induced diabetic mouse 
model (NOD-SCID T1D mice), post-transplantation of p53sh human EPCs (silenced by 
adenovirus) . Type 1 diabetes was induced in NOD.CB17-Prkdcscid/J mouse (NOD-SCID) by 
streptozotocin (STZ). Human CD34 + ve cells were transduced with Adenovirus constructs to 
silence p53 and p21. Then, p53sh and p21sh human CD34+ ve cells were transplanted to mouse 
right hind limb muscle post occlusion of femoral artery. Gene expression analysis was performed in 
quadriceps muscle after mice were sacrificed at day 28 post surgery. In this figure we demonstrate 
mRNA expression of IL6 (an inflammatory marker) gene analysis of the quadriceps muscle that 
received Saline, Ad-Null transduced CD34+ve cells or Adp53-sh transduced CD34+ve cells. The 
quadriceps muscle that received p53 sh CD34+ve cells should the least IL6 expression  indicating 
inflammation reduction property of p53sh transplanted cells (Statistical analysis was performed by 
using saline receiving muscle and and null receiving muscle as control, * indicates p-value <0.05 ).  
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